FDA Inspection 1265006 — MP Biomedicals Asia Pacific Pte Ltd
The FDA completed an inspection of MP Biomedicals Asia Pacific Pte Ltd on Mar 21, 2025 in Singapore. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 2 citations were issued during this inspection. Product area: Biologics.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Mar 21, 2025
- Fiscal Year
- 2025
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Singapore (Singapore)
Citations
| ID | CFR | Description |
|---|---|---|
| 3206 | 21 CFR 820.50(b) | Approval, inadequate purchasing data |
| 541 | 21 CFR 820.70(c) | Environmental control Lack of or inadequate procedures |